In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy
Source abstract
Abstract
Liver cancer is the most common malignant tumor and liver cancer immunotherapy has been one of the research hotspots. To induce antigen-specific antitumor immune responses against liver cancer, we developed antigen and adjuvant co-delivery nanovaccines (APPCs). Polyanionic alginate (ALG) and polycationic polyethyleneimine (PEI) were utilized to co-deliver a glypican-3 peptide antigen and an unmethylated cytosine-phosphate-guanine (CpG) adjuvant by electrostatic interactions. A cellular uptake study confirmed that APPC could promote antigen and adjuvant uptake by dendritic cells (DCs). Importantly, APPC facilitated the endosomal escape of the peptide for antigen delivery into the cytoplasm. In addition, APPC showed significant stimulation of DC maturation in vitro. APPC could also efficiently prime DCs and induce cytotoxic T lymphocyte responses in vivo. The in vitro cell viability assay and the in vivo histocompatibility showed that APPC was non-toxic within the tested concentration. This study demonstrates that the peptide antigen and the CpG adjuvant co-delivery nanovaccine have potential applications in liver cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Tianjin Key Laboratory of Biomaterial Research, Biomedical Barriers Research Center, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China
Department of Gastroenterology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi city, 214002, China
Department of Gastroenterology, Wuxi No. 2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi city, 214002, China
State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300353, China
Funding
National Natural Science Foundation of China · State Key Laboratory of Medicinal Chemical Biology · Wuxi Health and Family Planning Commission · Peking Union Medical College · Chinese Academy of Medical Sciences Initiative for Innovative Medicine · Wuxi Municipal Bureau on Science and Technology
References (43)
Show source-provided references
1. Siegel · CA Cancer J. Clin. · 2020 · 70 · 710.3322/caac.21590 ↗
2. Tagliamonte · Curr. Opin. Immunol. · 2016 · 39 · 10310.1016/j.coi.2016.01.005 ↗
3. Chen · Mater. Today · 2019 · 25 · 6610.1016/j.mattod.2018.10.040 ↗
4. Bruix · Nat. Rev. Gastroenterol. Hepatol. · 2019 · 16 · 61710.1038/s41575-019-0179-x ↗
5. Prieto · Nat. Rev. Gastroenterol. Hepatol. · 2015 · 12 · 68110.1038/nrgastro.2015.173 ↗
6. Elsegood · Clin. Transl. Immunol. · 2017 · 6 · e16110.1038/cti.2017.47 ↗
7. Tang · Cancer Lett. · 2016 · 370 · 8510.1016/j.canlet.2015.10.009 ↗
8. Zou · Cell. Mol. Immunol. · 2018 · 15 · 41910.1038/s41423-018-0011-5 ↗
9. Goldberg · Nat. Rev. Cancer · 2019 · 19 · 58710.1038/s41568-019-0186-9 ↗
10. Mu · ACS Appl. Mater. Interfaces · 2019 · 11 · 2359110.1021/acsami.9b05526 ↗
11. Zhou · Med. Res. Rev. · 2018 · 38 · 74110.1002/med.21455 ↗
12. Zhang · Medicine · 2018 · 97 · e1113010.1097/MD.0000000000011130 ↗
13. Montalbano · Cell. Oncol. · 2018 · 41 · 16910.1007/s13402-017-0364-2 ↗
14. Shimizu · Cancer Sci. · 2018 · 109 · 53110.1111/cas.13485 ↗
15. Wu · Mol. Ther. · 2017 · 25 · 229910.1016/j.ymthe.2017.08.005 ↗
16. Sawada · Int. J. Oncol. · 2015 · 46 · 2810.3892/ijo.2014.2737 ↗
17. Zhang · Acta Pharm. Sin. B · 2020 · 10 · 203710.1016/j.apsb.2020.07.013 ↗
18. Kandasamy · Nanotechnol. Rev. · 2018 · 7 · 31710.1515/ntrev-2018-0013 ↗
19. Pasquale · Vaccines · 2015 · 3 · 32010.3390/vaccines3020320 ↗
20. O'Hagan · Vaccine · 2015 · 33 · B1410.1016/j.vaccine.2015.01.088 ↗
21. Braunstein · Target. Oncol. · 2018 · 13 · 58310.1007/s11523-018-0589-7 ↗
22. Aranda · OncoImmunology · 2014 · 3 · e2917910.4161/onci.29179 ↗
23. Li · Adv. Healthcare Mater. · 2013 · 2 · 130910.1002/adhm.201200364 ↗
24. Miyamoto · Bioconjugate Chem. · 2017 · 28 · 56510.1021/acs.bioconjchem.6b00675 ↗
25. Zhu · Acta Pharm. Sin. B · 2020 · 10 · 205410.1016/j.apsb.2020.08.010 ↗
26. Singh · J. Biomed. Nanotechnol. · 2014 · 10 · 214910.1166/jbn.2014.1958 ↗
27. Ueno · Adv. Food Nutr. Res. · 2014 · 72 · 9510.1016/B978-0-12-800269-8.00006-3 ↗
28. Venkatesan · Int. J. Biol. Macromol. · 2015 · 72 · 26910.1016/j.ijbiomac.2014.07.008 ↗
29. Zhang · Nanoscale · 2017 · 9 · 330410.1039/C7NR00005G ↗
30. Hao · Biotechnol. Bioprocess Eng. · 2015 · 20 · 55010.1007/s12257-014-0858-y ↗
31. Mimi · J. Controlled Release · 2012 · 158 · 12310.1016/j.jconrel.2011.10.035 ↗
32. Zhu · ACS Appl. Mater. Interfaces · 2018 · 10 · 3495410.1021/acsami.8b12355 ↗
33. Zhang · Mol. Pharm. · 2017 · 14 · 176010.1021/acs.molpharmaceut.7b00015 ↗
34. Guan · Biomaterials · 2018 · 171 · 19810.1016/j.biomaterials.2018.04.039 ↗
35. Shi · Biomaterials · 2017 · 113 · 19110.1016/j.biomaterials.2016.10.047 ↗
36. Manolova · Eur. J. Immunol. · 2008 · 38 · 140410.1002/eji.200737984 ↗
37. Mohsen · J. Controlled Release · 2017 · 251 · 9210.1016/j.jconrel.2017.02.031 ↗
38. Roberts · Cancer Cell · 2016 · 30 · 32410.1016/j.ccell.2016.06.003 ↗
39. Muraoka · J. Immunol. · 2010 · 185 · 376810.4049/jimmunol.0903649 ↗
40. Wang · Adv. Healthcare Mater. · 2019 · 8 · e190047410.1002/adhm.201900474 ↗
41. Garris · Immunity · 2018 · 49 · 114810.1016/j.immuni.2018.09.024 ↗
42. Yin · Immunology · 2017 · 152 · 28710.1111/imm.12768 ↗
43. Zhu · Biomaterials · 2019 · 206 · 2510.1016/j.biomaterials.2019.03.012 ↗